Key result
Treatment with propranolol, carbimazole, and potassium supplementation led to complete resolution of quadriparesis and respiratory distress in a patient with thyrotoxic periodic paralysis.
Case Report (n=1)
Thyrotoxic periodic paralysis can present as acute quadriparesis and is treatable with beta-blockers and antithyroid medications.
TPP as first thyrotoxicosis sign supports thyroid testing in hypokalemic paralysis; leaves open validation in prospective cohorts.
Thyrotoxic periodic paralysis (TPP) is an uncommon disorder characterized by acute onset of hypokalemia (serum potassium level less than 3.5 mmol/L) and paralysis secondary to thyrotoxicosis. Patients can present with TPP as the first clinical manifestation of thyrotoxicosis. In patients presenting with acute episodes, the presence of hypokalemia and elevated levels of thyroid hormones with low thyroid-stimulating hormone levels (less than 0.35 µIU/mL) are important diagnostic clues. We report one case of TPP in which the acute onset of paralysis was the first clinical presentation of underlying thyrotoxicosis. After treatment with propranolol and carbimazole, the patient became symptom-free and euthyroid.
No takes yet. Share an insight, caveat, or question.
Kaeley et al. (2022) conducted a case report in Thyrotoxic periodic paralysis (n=1). Propranolol, carbimazole, and potassium supplementation was evaluated on Resolution of symptoms. Treatment with propranolol, carbimazole, and potassium supplementation led to complete resolution of quadriparesis and respiratory distress in a patient with thyrotoxic periodic paralysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: